By Colin Kellaher
Shares of ViewRay Inc. lost more than a third of their value and hit a new 52-week low on Thursday after the radiation therapy system maker slashed its revenue guidance and said it would explore strategic alternatives, including a sale of the company.
ViewRay said it now expects revenue will be flat to up 15% this year, compared with a prior growth forecast of 25% to 40%.
The company also said its adjusted Ebitda loss this year would be wider than previous estimates.
ViewRay said it hired Goldman Sachs & Co. as an adviser to review its options, including a possible sale, merger or business combination.
ViewRay shares were recently changing hands at $1.96, down 35%, after hitting a 52-week low of $1.92 earlier in the session.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 13, 2023 11:43 ET (15:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.